| STARTSEITE |
 |
|
| Impressum |
| Datenschutz |
 |
 |
| SPOT ON | |
DPP-4 inhibitors - clinical benefit still unproven | |
| NEW ON THE MARKET | Lisdexamfetamine (ELVANSE) as second-line therapy for treatment-refractory attention deficit hyperactivity disorder? |
| THERAPY FROM A CRITICAL VIEWPOINT | Vaccination against rotavirus for all infants? |
| a-t READERS' QUESTIONS AND COMMENTS |
Which contraceptive to use after venous thromboembolism? |
| IN BRIEF | Enough: 30 years of flunitrazepam (ROHYPNOL, generics) |
| CURRENT ADR NETWORK REPORT | |
Angioedema with ALMASED powder | |
| SIDE EFFECTS | |
Progressive multifocal leukoencephalopathy (PML) with fingolimod (GILENYA) Promotion of quinine (LIMPTAR N) against leg cramps New warnings and contraindications for mefloquine | |
| e a-t IN INTERNET | |
 |
Anaphylactic reactions with chlorhexidine (e.g. CHLORHEXAMED) |
|
© arznei-telegramm 9/2013 | ||
 | ||